BioSpace News Archive

Impel Pharmaceuticals Inc. announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced an oral presentation by key thought leader David Boyer, M.D. at the 45th Annual Macula Society Meeting.

Astellas Pharma Inc. announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C.

OnCusp Therapeutics announced today a licensing agreement with Multitude Therapeutics for the development and commercialization of AMT-707 (now referred to as CUSP06), a potentially highly differentiated second-in-class CDH6 antibody drug conjugate (“ADC”).

LenioBio GmbH today announced it had achieved a key milestone for the company with the successful linear scaling of its cell-free protein synthesis (CFPS) platform, ALiCE®, to an industrial scale.

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension.

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), (“Alpha Tau” or the “Company”), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the Company’s Investigational Device Exemption (IDE) application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using the Alpha DaRT.

Innova Medical Group, Inc., today announced it successfully earned its CE mark certification (certificate N° 39032) of the Innova SARS-CoV-2 Antigen Rapid Qualitative Self-Test through GMED LNE Group, a leading certification organization and a distinguished Notified Body of the European Commission covering a vast range of products covered under both Invitro Diagnostic and Medical Device Regulations.

Royal Philips announced the publication of its Future Health Index 2022 report: ‘Healthcare hits reset: Priorities shift as healthcare leaders navigate a changed world’.

The global proteomics market is expected to reach a market size of USD 65.91 billion by 2028 and register a high CAGR during the forecast period, according to a new report by Reports and Data.